| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/26/2002 | WO2002074237A2 Compositions and methods for the therapy and diagnosis of kidney cancer |
| 09/26/2002 | WO2002074232A2 Antitumor compositions containing taxane derivatives |
| 09/26/2002 | WO2002074231A2 Cosmetic and dermopharmaceutical compositions comprising standardised extracts of hierochloe odorata |
| 09/26/2002 | WO2002074230A2 A dna molecule encoding a variant paraoxonase and uses thereof |
| 09/26/2002 | WO2002074229A2 A combination comprising combretastatin and anticancer agents |
| 09/26/2002 | WO2002074050A2 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |
| 09/26/2002 | WO2002074048A2 P-glycoproteins and uses thereof |
| 09/26/2002 | WO2002074042A2 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 09/26/2002 | WO2002074036A2 Substituted benzopyranones as telomerase inhibitors |
| 09/26/2002 | WO2002062999A8 Proteins and nucleic acids encoding same |
| 09/26/2002 | WO2002060455A8 Methods and compositions utilizing 2'-5' oligoadenylates in the treatment of disorders of cell proliferation |
| 09/26/2002 | WO2002060382A3 Novel compounds and uses thereof |
| 09/26/2002 | WO2002056755A3 Method for treating cancer |
| 09/26/2002 | WO2002055517A3 4-(hetero)aryl substituted indolinones |
| 09/26/2002 | WO2002053581A3 Spliceosome mediated rna trans-splicing |
| 09/26/2002 | WO2002040484A3 Novel imidazole derivatives, production method thereof and use thereof |
| 09/26/2002 | WO2002032872A8 Nitrogenous aromatic ring compounds |
| 09/26/2002 | WO2002030922A3 Dioxolane analogs for improved inter-cellular delivery |
| 09/26/2002 | WO2002028810A3 Retinoids for the treatment of emphysema |
| 09/26/2002 | WO2002026996A3 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 09/26/2002 | WO2002026954A3 Truncated phosphodiesterase-7 polypeptides |
| 09/26/2002 | WO2002024692A8 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors |
| 09/26/2002 | WO2002024636A3 N-acylsulfonamide apoptosis promoters |
| 09/26/2002 | WO2002022685A3 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001090159B1 Compositions and methods for delivery of a molecule into a cell |
| 09/26/2002 | WO2001087343A3 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001076568A3 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 09/26/2002 | WO2001073002A3 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 09/26/2002 | WO2001072695A1 Neovascularization inhibitors |
| 09/26/2002 | WO2001051051B1 AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS |
| 09/26/2002 | WO2001047953A3 Antibodies against plasma cells |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001023421A9 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | WO2001019861A9 Apo-2 receptor antibodies |
| 09/26/2002 | WO2001019823A9 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/26/2002 | WO2000074634A9 Methods and compositions for modulating cell proliferation and cell death |
| 09/26/2002 | WO2000061112A3 Solubilized pharmaceutical composition for parenteral administration |
| 09/26/2002 | WO1997019953A8 New lh-rh antagonists with improved effectiveness |
| 09/26/2002 | US20020137955 Reaction of an oxazole compound, (phenylisoserine derivative) with a hydroxyl-protected Baccatin III derivative to produce a taxane substrate that can be used to form paclitaxel and other taxanes |
| 09/26/2002 | US20020137941 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 09/26/2002 | US20020137927 Intermediates in the preparation of sidechain-bearing taxanes such as taxol and taxol derivatives. |
| 09/26/2002 | US20020137910 MN gene and protein |
| 09/26/2002 | US20020137907 Novel compounds |
| 09/26/2002 | US20020137892 An isolated peptide transmitter-like receptor polypeptide with specific amino acid sequence or variant which has immunomodulatory, neuromodulatory and endocrinomodulatory activity |
| 09/26/2002 | US20020137801 Administering gossypol; kits to treat patients |
| 09/26/2002 | US20020137798 Treatment of disorders secondary to organic impairments |
| 09/26/2002 | US20020137797 Alpha-Difluoromethylornithine (DFMO) suppresses polyamine levels in the human prostate |
| 09/26/2002 | US20020137789 Anticancer agents |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137776 Therapeutic and prophylactic agents for neoplasms |
| 09/26/2002 | US20020137775 Novel delta dicarbonyl compounds and methods for using the same |
| 09/26/2002 | US20020137770 Piperidine derivatives |
| 09/26/2002 | US20020137769 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
| 09/26/2002 | US20020137757 Quinazolines and therapeutic use thereof |
| 09/26/2002 | US20020137755 Tyrosine kinase inhibitors |
| 09/26/2002 | US20020137748 Reducing intestinal toxicity of a noncompetitive thymidylate synthase inhibitor by co-administering a folate derivative without blocking therapy; anticancer, antitumore agents |
| 09/26/2002 | US20020137744 Metalloprotease inhibitors |
| 09/26/2002 | US20020137732 Small molecule inhibitors targeted at Bcl-2 |
| 09/26/2002 | US20020137731 Killing cancer cells with vitamin D3 analog ILEX 23-7553 of given structure and ionizing radiation |
| 09/26/2002 | US20020137714 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137679 Thrombospondins-1 and -2 are adhesive glycoproteins proteins that are angiogenesis inhibitors; portions of TSP- 1, TSP-2, endostatin, angiostatin, platelet factor 4, or prolactin linked to a portion of cartilage oligoeric matrix protein |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137663 The anti-neoplastic agent ET-743 inhibits trans activation by SXR |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137184 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof |
| 09/26/2002 | US20020137182 For obtaining and using a polypeptide other than oncogene BCL-2 that affects programmed vertebrate cell death |
| 09/26/2002 | US20020137170 Dual-specificity protein tyrosine phosphatases that dephosphorylate both phosphotyrosine and phosphothreonine/serine residues |
| 09/26/2002 | US20020137166 ASIP-related proteins |
| 09/26/2002 | US20020137155 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher Basidiomycetes mushroom |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137109 Anticarcinogenic agents;monitoring therapy efficiency |
| 09/26/2002 | US20020137086 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| 09/26/2002 | US20020137038 Intestinal proteins |
| 09/26/2002 | US20020136819 Conserved concentrations of cocoa polyphenols by mixing carbohydrate or protein containing ingredients with a polyphenol conserving pretreatment ingredient and then with a cocoa polyphenol |
| 09/26/2002 | US20020136784 Cyclooxygenase-2 (COX-2); administering a plant extract; nonsteroidal anti-inflammatory agents |
| 09/26/2002 | US20020136744 Sustained release drug dispersion delivery device |
| 09/26/2002 | US20020136737 Isolated nucleic acids comprising Listeria dal and dat genes |
| 09/26/2002 | US20020136736 Or prophylactically or therapeutically effective fragment thereof in admixture with a pharmaceutically acceptable carrier |
| 09/26/2002 | US20020136735 Preparations that potentiate immunogenicity in low immunogenic antigens |
| 09/26/2002 | US20020136731 Targeted therapeutic delivery of vitamin D compounds |
| 09/26/2002 | US20020136729 Combined physical and immunotherapy for cancer |
| 09/26/2002 | US20020136726 Method for selectively delivering agent to arterial smooth muscle cells in mammal comprising administering agent and substance which selectively binds arterial smooth muscle cell-specific surface molecule selected from ephrin family |
| 09/26/2002 | US20020136720 Methods of using IMXP-888 and IMXP-888 antagonists |
| 09/26/2002 | US20020136719 For biomedical applications, including biological delivery to humans and animals |
| 09/26/2002 | US20020136717 Process for screening chemical compounds for modulating the interaction of an EVH1 domain or a protein having an EVH1 domain with an EVH1 binding domain or a protein having an EVH1 binding domain, and a process for detecting said interaction |
| 09/26/2002 | US20020136715 Composition comprising a binding agent that specifically binds to circulating prostate specific antigen and induces a therapeutic immune response |
| 09/26/2002 | US20020136689 Antibody which specifically binds to prostate stem cell antigen on surface of carcinoma cells and is internalized within carcinoma cells to which it binds |
| 09/26/2002 | DE10113402A1 New N,N'-bis-(Aminocarbonyl)-hydrazine derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, apoplexy, restenosis or tumors |
| 09/26/2002 | DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections |
| 09/26/2002 | CA2469846A1 New interferon beta-like molecules |
| 09/26/2002 | CA2460779A1 Use of gram-negative bacterial membrane fraction for inducing the maturation of dendritic cells |
| 09/26/2002 | CA2448795A1 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent |
| 09/26/2002 | CA2445374A1 Process for producing lactic acid oligomer |
| 09/26/2002 | CA2444526A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2441822A1 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |